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1Abstract
A widely used approach for dealing with locus heterogeneity in linkage analysis is based
on mixture likelihood, in which a single mixing (heterogeneity) parameter represents the
probability that each family is of linked type. However, in general, dierent types of families
exhibit dierent heterogeneity levels. To incorporate this variability, we propose a new ap-
proach, wherein each family has its own heterogeneity parameter representing the probability
that it is of linked type. These parameters are nuisance parameters while the main param-
eter of interest is the location of the disease gene, if there is any. We model the problem in
the Bayesian framework and implement it using the Markov chain Monte Carlo (MCMC)
methodology. In particular, we utilize the reversible jump MCMC sampler to move between
the two models: linkage and no linkage. We rst estimate the posterior probability of linkage
on a chromosome and the corresponding Bayes factor. If linkage is inferred, the location of
the disease gene along with its credible set is estimated. The asymptotic joint distribution of
the estimators is derived. We show that this approach is more powerful than the currently
used approach in detecting linkage while the two approaches have comparable false positive
rates. The proposed method was applied to a lung cancer dataset of Genetic Epidemiology
of Lung Cancer Consortium and an asthma dataset consisting of three samples from Genetic
Analysis Workshop 12. Since both lung cancer and asthma are complex traits with hetero-
geneous genetic predisposition, they provide suitable applications for the proposed method.
Keywords
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21 INTRODUCTION
Locus heterogeneity is one of the major reasons for limited success of linkage analysis in
mapping genes that inuence complex genetic traits. This phenomenon refers to the situa-
tions when a disease is caused in some families by one gene while in other families it is caused
by some other gene and/or non-hereditary factors. The most popular approach currently
used for incorporating heterogeneity is the admixture approach (Ott 1999). It uses a sin-
gle heterogeneity (mixing) parameter, , to model the probability that the disease-causing
gene of a family is linked to a reference map of markers, i.e., a family is of linked type.
A mixture likelihood based on the two parameters, , and the location of disease gene, is
formed. The overall LOD score (log10 of likelihood ratio) based on this mixture likelihood,
referred to as the heterogeneity LOD (HLOD) score, is then maximized with respect to the
parameters (Ott 1999). Notwithstanding its wide usage, several limitations of the admixture
approach have been pointed out in the literature (see e.g., Janssen, Halley, and Sandkuijl
1997; Vieland, Wang, and Huang 2001; Whittemore and Halpern 2001; Vieland and Logue
2002). In particular, we have shown recently that a single heterogeneity parameter is insuf-
cient to capture the variable rates of heterogeneity across dierent types of families, and
hence can lead to inconsistent estimators (Lin and Biswas 2004; Biswas and Lin 2004).
In this article, we propose a new approach by assigning to each family its own hetero-
geneity () parameter that denotes the probability that it is of linked type. However, the
large number of parameters involved in such a model poses a big challenge that cannot be
handled by the traditional approaches. A viable alternative to circumvent this problem is
provided by the Markov chain Monte Carlo (MCMC) methodology. These methods have
signicantly broadened the scope of modeling the complexities in many applications (Gilks,
Richardson, and Spiegelhalter 1996). To take advantage of the MCMC techniques, we cast
our problem in a Bayesian framework. The  parameters are nuisance parameters while the
main parameter of interest is the location of the disease gene. Being in the Bayesian setting,
we focus on obtaining the posterior distributions of the parameters. These distributions are
estimated by drawing a large number of dependent samples via realizations of a Markov chain
whose stationary distribution is the joint posterior distribution of all parameters. Due to the
3need of switching between subspaces of dierent dimensionality created by the linked and
unlinked states, we employ the reversible jump MCMC method (Green 1995). The Bayesian
approach has been evaluated and compared with the usual two-parameter admixture ap-
proach through simulations. We also performed a sensitivity analysis on the specications
of the priors. In addition, the robustness of this approach to model misspecication is stud-
ied by analyzing the Genetic Analysis Workshop (GAW) 13 simulated dataset, which was
modeled after the Framingham Heart Study (Almasy et al. 2003). We applied the proposed
Bayesian approach to two real datasets: a lung cancer dataset of Genetic Epidemiology of
Lung Cancer Consortium (GELCC; Bailey-Wilson et al. 2004) and the GAW 12 asthma
dataset (Wijsman et al. 2001).
Lung cancer has a severe mortality rate reected in the fact that it claims more lives than
breast, colon, and prostate cancers combined. While smoking and other behavioral and en-
vironmental factors play a major role in lung cancer, numerous studies point to involvements
of genetic factors in familial lung cancer (FLC). Bailey-Wilson et al. (2004) reviewed these
studies and conducted a genome-wide linkage analysis to identify susceptibility genes. They
used the data collected by the FLC recruitment sites of GELCC and computed HLOD. No
signicant linkage signal was detected when the full dataset was analyzed. This suggests that
perhaps there are varying rates of heterogeneity among the families in the full dataset, and
HLOD, being unable to account for it, suers power loss. Since our approach is designed to
explicitly account for variable levels of heterogeneity among dierent families, we anticipate
that it may have the power to detect linkage in the whole dataset.
Asthma is one of the most common chronic childhood diseases in the developed countries.
It is a complex disease caused by the interplay of multiple genetic and/or environmental
factors. Although several studies have been carried out to dissect the genetic mechanism
of asthma, many of them have produced contradictory results; this undesirable situation
is largely attributed to the presence of heterogeneity (Wijsman et al. 2001). Of the three
asthma samples that are analyzed in the current paper, two comprise Caucasian families
while the other one has African-American families. Eerdewegh et al. (2001) found that an
overall HLOD obtained by pooling the three samples suers substantial power loss, causing
its failure to nd linkage signals. The most plausible explanation is the presence of dierent
4ethnicities, which often exhibit dierent levels of heterogeneity. Indeed, a common conclusion
from various investigations of the three samples is that, unlike the two Caucasian samples,
the African-American sample consists mostly of unlinked type of families for chromosome
6 (Eerdewegh et al. 2001; Wang, Huang, Logue, and Vieland 2001; Biswas and Lin 2004).
The Bayesian paradigm lends a natural way to incorporate this a priori information about
heterogeneity across ethnicities into the analysis. We expect that such a strategy will help
in identifying linkage signals, thereby demonstrating the exibility of the method.
2 METHODS
2.1 Model
We focus on one chromosome at a time to search for disease gene(s). Suppose there are
k families in the sample. Let j be the probability that the jth family is of linked type,
j = 1;:::;k, and d be the position of the disease gene on the chromosome. Also let xj
and Lj(djxj) denote the observed data and the corresponding (homogeneity) likelihood,
respectively, of the jth family, j = 1;:::;k. Denote x = (x1;x2;:::;xk) and  = (1;:::;k).
Here  is a set of nuisance parameters. Then the likelihood is given by
L(;djx) =
k Y
j=1
[jLj(djxj) + (1   j)Lj(1jxj)]:
Here Lj(1jxj) denotes the likelihood of the data when the disease gene is at distance \1"
from the marker map, i.e., it is unlinked to the chromosome. Suppose there are N distances
at which the LOD scores are calculated on the chromosome. We label the indexes of these
N distances as 1;:::;N. Let Id denote the index of distance d. Then Id 2 f1;:::;Ng.
Note that computing LOD scores at a pre-specied grid of points across the chromosome
is a usual practice in linkage analysis since analytical forms of likelihoods are usually not
available except for a few simple pedigree structures (Ott 1999).
Prior distribution for d consists of two components: one when there is a disease gene
present on the chromosome of interest (d < 1) and another when there is no such disease
gene (d = 1), with prior probabilities d<1 and d=1, respectively. Further, for d < 1,
5there is a probability distribution of d (location of disease gene) denoted by d(Id). This
is a probability mass function on the N distances at which the LOD scores, and hence the
likelihoods, are calculated. Next, let the prior distribution of j (j = 1;:::;k) be j(j).
These distributions may not be identical but they are assumed to be independent of each
other and are also independent of the distribution of d when d < 1. Note that j's are
meaningless when d = 1. So, now we can write the joint posterior distribution of (;d) as
(;djx) /
"
k Y
j=1
j(j)
#I(d<1) h
d<1d(Id)I(Id 2 f1;:::;Ng) + d=1I(d = 1)
i

k Y
j=1
[jLj(djxj) + (1   j)Lj(1jxj)];
where the likelihood factor reduces to
Qk
j=1 Lj(1jxj) when d = 1, independent of the 
parameters. The goal is to obtain the posterior distributions of j's and d. In the next
section, we propose an MCMC scheme that generates a Markov chain whose stationary
distribution is the joint posterior distribution. To be more precise, we note that there are,
in fact, two posterior distributions depending on whether d < 1 or d = 1 (point mass),
corresponding to the linked and unlinked models, respectively. Notice that d<1 and d=1
are the prior probabilities of these two models. An initial part of the chain (burn-in period),
after which the chain is believed to have navigated into the target posterior distribution, is
discarded. The chain is then allowed to run for a suciently large number of iterations so
that it covers the target distribution reasonably well.
2.2 MCMC Sampling Scheme
The values of d < 1 (linked subspace) and d = 1 (unlinked subspace) lead to two dierent
models with dierent numbers of parameters. The linked subspace (L) consists of k + 1
parameters (;d) while the unlinked subspace (U) has no parameters, since d = 1 renders
the 's meaningless. So, we need to use a sampler that allows moves to be made between
dierent models with dierent number of parameters. The sampling scheme described here
uses a reversible jump MCMC sampler (Green 1995; Richardson and Green 1997) to enable
moves to be made from L to U and vice versa. For updating the j's and d, when the
6chain is currently in the L subspace, we use the Gibbs sampler (Geman and Geman 1984)
and Metropolis-Hastings algorithm (Metropolis, Rosenbluth, Rosenbluth, Teller, and Teller
1953; Hastings 1970), respectively.
Suppose the probability of staying in the L subspace given that the current state is in
L, denoted by P(LjL), is 1. Similarly, let P(UjU) be 2. Hence P(UjL) and P(LjU)
are 1   1 and 1   2, respectively. At iteration t, rst we randomly choose whether a
move to the other subspace is proposed or not, according to one of the above probabilities.
Depending on the current and the proposed states, there are four possible types of moves:
L ! L, L ! U, U ! U, and U ! L, where the letter on the left (right) side of ! is the
subspace of the current (proposed) state. We note that the moves as described here resemble
a random walk scheme and are slightly dierent from the sweeping moves described in some
of the reversible jump algorithm literature (e.g., see Richardson and Green 1997). However,
there is a correspondence between the two: the moves U ! L and L ! U, which alter the
dimension of the parameter space, would be called birth and death of a gene, respectively,
in the usual terminology of the reversible jump algorithm; the other two moves, L ! L and
U ! U form the so-called updating of parameters moves. Detailed description of these four
move types is given in Appendix A.
Starting with some initial values for (;d), we run the Markov chain for a burn-in pe-
riod of B iterations. After this, the chain is run for another T iterations. The posterior
distributions are estimated based on these T iterations.
2.3 Inference Using Posterior Distribution
Our interest lies in drawing inference about the disease gene location, so we focus on the
marginal posterior distribution of d. It can be viewed as a mixture of point mass at 1 and
a distribution for the location of the disease gene on the chromosome, under linkage, i.e.,
(djx) = P(d = 1jx)I(d = 1) + P(d < 1jx)P(djd < 1;x)I(d < 1):
P(d = 1jx) and P(d < 1jx) can be interpreted as the posterior probability of no linkage
and linkage on the chromosome, respectively. Let ti denote the number of times the distance
with index i is in the MCMC output of the T iterations, i = 1;:::;N, thus
P
i ti is the
7number of times that the chain stays in the L subspace. We also denote by t1 the number
of times the chain is in the U subspace. Then, the estimate of the posterior distribution of
d as obtained from the MCMC output can be written as
^ (djx) =
t1
T
I(d = 1) +
T   t1
T
N X
i=1
ti
T   t1
I(Id = i)
= ^ P(d = 1jx)I(d = 1) + ^ P(d < 1jx)
N X
i=1
^ P(d = dijd < 1;x)I(Id = i);
where di is the distance with index i, i = 1;:::;N. The rst term in the above expression
is a point mass at d = 1. From the above representation, it is clear that ^ p = (T   t1)=T
(proportion of times the chain is in the L subspace) is the estimated posterior probability
of linkage. The larger the value of ^ p, the greater the signal for linkage on that chromosome.
Under linkage, the mean of the estimated posterior distribution of d when the chain is in the
L subspace, given by
^ m =
PN
i=1 tidi
PN
i=1 ti
=
PN
i=1 tidi
T   t1
;
is an estimate of the location of a disease gene.
From the above discussion, we see that the estimators that summarize the posterior
distribution of d are (^ p, ^ m). Note that ^ m is meaningful only under linkage. At this point, it is
worth noting that although the Markov chain output consists of the sequence f((t);d(t));t =
1;2;:::;Tg, for some t, (t) vanishes and d(t) = 1 (when the chain moves to the U subspace).
Further, since d is the parameter of interest, the estimators (^ p, ^ m) are based only on the
fd(t);t = 1;2;:::;Tg component of the MCMC output. Although this may seem a bit
peculiar in the usual MCMC scenario, this peculiarity alleviates when we view it from the
perspective of model determination, where the two models are linkage and no linkage, each
having a dierent number of parameters. One way of comparing between the linkage and no
linkage models is via the Bayes Factor (BF), which can be estimated by
d BF =
^ p=(1   ^ p)
d<1=d=1
=
^ p=(1   ^ p)
d<1=(1   d<1)
:
An attractive feature of BF is that it is theoretically independent of the prior, d<1 (Richard-
son and Green 1997); inference under BF does not need to reference the prior used. For a
8xed d<1, d BF is a strictly increasing function of ^ p, and so d BF exceeding a pre-specied
threshold BF0 can be used to conclude linkage.
It can be shown that the joint asymptotic distribution of (^ p, ^ m) is Bivariate Normal
(BVN) with means (p, m), where p is the true posterior probability of linkage and m is
the true location of the disease gene under linkage. The proof of this result along with the
expressions for variances and correlation are in Appendix B.
In addition to estimating the disease gene location under linkage (m) by ^ m, we also
obtain its interval estimates. We explore two ways of getting such an estimate. First, we
could get a classical condence interval by using the asymptotic normality property of ^ m
and estimating the SE of ^ m by batch means method. In fact, we can get more than this - if
we use the asymptotic bivariate normality property of (^ p, ^ m), then we can get simultaneous
condence intervals for (p, m). Another way of obtaining an interval estimate for m is to
compute a Bayesian credible set. A level (1 )% credible set is given by the interval covered
between =2th and (1   )=2th quantiles of the posterior distribution of d under linkage.
2.4 Diagnostics
For drawing valid inference from an MCMC procedure, we need to ensure that mixing of
the chain is good and it converges to its stationary distribution. Here we use two diagnostic
tools. The rst one is a simple graph wherein we plot the estimators ^ p and ^ m obtained
from dispersed starting points at every 100th iteration; this allows us to visually monitor
the chain.
The second one, a more formal tool, is to test independence of batch means. This also
serves the purpose of checking the assumption of independent batch means needed for the
batch means approach of computing variances. Divide the total chain (excluding the burn-
in) into R batches, each of length L. Let d
(l)
r denote the lth value of distance in the rth batch,
l = 1;2;:::;L; r = 1;2;:::;R. For batch means yr =
PL
l=1 d
(l)
r I(d
(l)
r < 1)=L, r = 1;:::;R,
we compute the Von Neumann statistic (Kleijnen 1987) given by
q =
PR 1
r=1 (yr   yr+1)
2
PR
r=1 (yr    y)
2 ;
9where  y =
PR
r=1 yr=R. Its standardized version is
Zy =
q   2
q
4(R 2)
R2 1
;
which has approximately N(0;1) distribution under the null hypothesis of independent batch
means. So the null hypothesis is rejected at  level of signicance if jZj > z=2. More
details can be found in Kleijnen (1987). Similarly we dene the statistic Zp for batch means
pr =
PL
l=1 I(d
(l)
r < 1)=L, r = 1;:::;R. We carry out the test of independence by dividing
the MCMC output into 100 batches and computing Zy and Zp while the batch means SE is
obtained using 30 batches, following Kleijnen (1987) and Schmeiser (1982).
3 SIMULATION RESULTS
The following is a description of the data and the simulation models used in all subsections
of this section. We simulated datasets along the lines of the GAW13 simulated data (Almasy
et al. 2003) and used GENEHUNTER (Kruglyak, Daly, Reeve-Daly, and Lander 1996) to
compute the LOD scores that are needed as input to our procedure. A sample consists of
274 GAW13 pedigrees (nuclear and extended families) which include the pedigree structures
that GENEHUNTER can analyze as a whole and some trimmed pedigrees. The family sizes
range from 7 to 19 members (mean = 11.2). For all simulations, except the homogeneity
model to be described later, we randomly chose the probability that a family is of a linked
type from the Beta(3,2) distribution. In addition to the pedigree structure, the observed
data for each family consist of marker genotypes and phenotypes (aection statuses) for
family members. Biswas, Papachristou, Irwin, and Lin (2003) labeled the aection status
of about 45% of the people to be missing for one of the replicates of the GAW13 data; we
kept those people's aection status missing in our simulated samples also. Unless stated
otherwise, we used the chromosome 21 markers with the same allele frequencies and inter-
marker distances as provided in GAW13. Specically, there are six markers on chromosome
21 at locations 0, 10.02, 22.74, 36.20, 40.07 and 59.53 cMs (adjusted such that the rst
marker is at 0 cM) with respective heterozygosities of 0.63, 0.73, 0.77, 0.74, 0.88 and 0.69.
For most of the simulations, we used the following disease model, where D is the disease
10allele and \A" denotes aected with the disease under study: disease allele frequency P(D)
= 0.2, and the penetrances for the three genotypes DD;Dd, and dd are P(A jDD) = 0.7,
P(A jDd) = 0.5, and P(A jdd) = 0.05. This model lies in-between dominant and recessive
models, the two classical Mendelian disease models, and we refer to it as a \intermediate"
model. We also carried out some simulations with a \dominant" model: P(D) = 0.05,
P(A jDD) = P(A jDd) = 0.5, P(A jdd) = 0.05, and a \recessive" model: P(D) = 0.1,
P(A jDD) = 0.7, P(A jDd) = P(A jdd) = 0.05. In addition, we also simulated under
a \homogeneity" model, i.e., all families being of linked type. For this simulation, we used
the recessive disease model described above.
We use the following prior distributions: j(j) is taken to be U(0;1), j = 1;:::;k,
d<1 = 1=22, d=1 = 21=22, and d(Id) = 1=N, Id = 1;:::;N. The rationale for the
chosen prior for d is as follows. Humans have 22 pairs of autosomes and one pair of sex
chromosomes. If we believe that the disease is not caused by a gene on the sex chromosomes,
then the probability that a randomly chosen chromosome has the disease gene is 1/22. Since
we compute LOD scores at N points on a chromosome, we evenly distribute the probability
mass at those N points. In some real data applications, the investigator may have some
a priori information about d and/or 's; such knowledge can be readily incorporated into
informative priors for the parameters. We used the non-informative priors for simulations
(except in the sensitivity study) to avoid inuence of any particular prior on our results
and subsequent comparison with the admixture approach. Nevertheless, as noted earlier,
changing the prior d<1 is unlikely to aect BF as BF explicitly takes d<1 into account.
We conclude linkage if d BF  BF0 = 25. According to Raftery (1996), a BF of at least 25
is considered to be a strong evidence for discriminating between two models.
3.1 Preliminary Analysis
We set the burn-in period of the Markov chain to be B = 10,000 iterations and after burn-in,
the chain is run for T = 300,000 iterations. To see if this chain length is adequate and gives
satisfactory mixing and convergence, we performed the diagnostics described in Section 2.4.
For a given sample, we ran the chain from seven dispersed starting points. After excluding
the burn-in period, we calculated ^ p and ^ m at every 100th iteration using the d values up to
11that point. Typical plots are shown in Figure 1. We note that the chains forget about their
starting points quickly and show nice convergence. We have also constructed the seven nal
95% condence intervals (CIs) computed using the batch means method for estimating SEs.
All seven CIs for both parameters overlap, although they are extremely narrow (this aspect
is discussed after the next paragraph). Similar pattern is seen in the plots for several other
samples generated with the disease gene location varying over the chromosome. Further, in
all the samples, the nal estimates, ^ p and ^ m obtained from all seven starting points, are very
close to each other.
We carried out the test of independence of batch means for several samples. For each
sample, the number of batches is 100, so the batch length is 3,000. Table 1 shows the two
test statistics, Zy and Zp for ve representative samples. These statistics show evidence of
independence of batch means at the 5% level for all samples, as none of the Zy or Zp values
fall into the rejection region. So, overall the diagnostic tools indicate that B = 10,000 and
T = 300,000 give satisfactory mixing and convergence of the chain.
Since all the d BF values exceed the cuto of 25 for declaring linkage, the disease gene
locations are estimated (^ m) and their corresponding interval estimates are also obtained, as
shown in Table 1. There are two interval estimates: the 95% CIs obtained using the batch
means method and the 95% Bayesian credible set (CS). As can be seen from the table, all
the CSs contain their corresponding disease gene locations while none of the 95% CIs does
so. Since the same results were obtained for all the other samples that we have considered,
it seems that the batch means estimator of SE is a severe underestimate of the true SE.
This is a known limitation of batch means estimators, although it is still used routinely
to report Monte Carlo errors, perhaps due to the fact that the extent of underestimation
is problem-dependent. We further increased the chain length but it did not alleviate the
problem. Although the true SE is unknown, we can estimate it from simulations (see next
section) and it leads us to conclude that batch means estimators of SEs would not be useful
in our case. So, in what follows, we do not consider batch means estimators any further.
123.2 Evaluation of Proposed Approach and Comparison with Ad-
mixture Approach
3.2.1 Bayesian versus Admixture
We carried out extensive simulations by placing the disease gene at various positions (5, 13,
25.64, 38, 49.77; in cM) on the chromosome and for each position we generated 500 samples
under the intermediate (Int) disease model. For each sample, we analyzed it using our
Bayesian approach, and the usual admixture approach with a single  parameter. For the
Bayesian approach, we estimated the posterior probability of linkage (^ p), the corresponding
Bayes Factor (d BF), the location of disease gene under linkage (^ m), and 95% CS for the
disease gene location. Summary statistics across all 500 samples are reported in the rst
segment of Table 2 (before the rst set of double horizontal lines). In particular, we report
the power (the percentage of the samples showing linkage signals, i.e., d BF > 25), and the
mean and SD of the ^ m's over the samples with linkage signals. Furthermore, we also present
the mean 95% CS among those samples with d BF > 25 and the percentage of these CSs
that contain the true value of the disease gene location. For the admixture approach, we
report the power (the percentage of samples in which HLOD is greater than 3), the mean
and SD of the estimated disease gene locations (positions at which maximum HLOD occurs)
over the samples with HLOD > 3. We use HLOD > 3 as a linkage signal for the admixture
approach because this cuto is customarily used in linkage analysis (Ott 1999), although it
has been now accepted that when one accounts for heterogeneity via admixture model, the
cuto should be higher (Abreu, Hodge, and Greenberg 2002). In traditional linkage analysis,
a condence interval (or support interval as it is sometimes referred to) may be obtained by
taking all the points whose LOD scores are within 1 unit of the maximum LOD score when
it exceeds 3 (Ott 1999). However, properties of such an interval is unclear in heterogeneity
analysis and hence we do not report them. We also compared the performances of the two
methods under the dominant (Dom), recessive (Rec), and homogeneity (Hom) models at the
disease gene position of 25.64 cM. The results are shown in the second segment of Table 2
(between the two sets of double horizontal lines).
From the table, we see that the proposed Bayesian approach is more powerful than the
13admixture approach. The relative increases in power range from 18% to 120%. Note that
if we had used the correct (higher) cuto for HLOD, the power of the admixture approach
would have gone down further. Moreover, there are no samples for which the admixture
approach can pick up a linkage signal while the Bayesian cannot. The mean and SD of the
estimated disease gene location are similar for both approaches. In general, it seems that the
Bayesian approach has a reasonably good power given the fact that there is so much missing
data. Missing data may also be a factor in the resulting 95% CSs being wide, although
the probabilities that these CSs contain the true value d is very high. Note that a negative
lower limit of a CS means that the CS contains positions beyond (below) the rst marker
whose position is set to 0 cM, a usual practice in linkage analysis. Compared to the others,
the position d = 49:77 gives the worst results by both methods. This is most likely due
to the fact that the two anking markers are farthest apart (19.46 cM) among all pairs of
consecutive markers.
3.2.2 Fine Mapping
We further evaluated the Bayesian approach in a ne mapping setting, which is the natural
next step after preliminary linkage is established. Equally importantly, this further investi-
gation should shed light on whether the seemingly wide CSs are partially due to the coarse
map, in addition to the missing data factor as discussed above. We focused on mapping the
gene at 25.64 cM, anked by the two central markers. We saturated the interval (12, 39.5)
(slightly overcovering the mean 95% CS reported in Table 2) with 12 new markers with 2.5
cM separation. Each new marker has four equally likely alleles, i.e., heterozygosity of 0.75,
which is approximately the average heterozygosity of the markers in the original map. In
addition to these new markers, the two original markers in this region are retained, leading
to a total of 14 markers for this study. Other than using this ner map of markers, the gener-
ation of the data and their analysis were carried out exactly as before under the intermediate
model. The results are shown in the last segment of Table 2. Compared to the results using
the original map (third row of the rst segment of the same table), we observe that, for
the Bayesian approach, both the SD and the mean 95% CS are cut by approximately half.
Further, the location estimate is much closer to the truth, and the power has also increased.
14However, for the admixture approach, although the power also rises sharply, the reduction in
SD is less impressive, resulting in its SD been considerably higher than that of the Bayesian
approach.
3.2.3 False Positive Rate
To gauge the false positive rates, we simulated 500 samples with no disease gene present on
the chromosome. The marker map is the same as the one used in all the other simulations
(except for ne mapping). Both Bayesian and admixture approaches gave 1 false positive. So,
the two approaches have comparable false positive rates, at least for the setting considered.
3.3 Sensitivity Study
We have varied the values of the proposal parameters, 1, 2, and s (in an L ! L move,
the updated value of d is chosen from the s neighboring distances of the current value of d;
see Appendix A) and found that they do not change the results qualitatively. This seems
to indicate that the proposed MCMC scheme is quite robust to the chosen values of these
proposal parameters. Also, the algorithm is insensitive to the chosen proposal distribution
for d in the U ! L move (denoted by Pi in Appendix A), since either setting all the Pi's to
be equal or generating the Pi's from a discretized, truncated normal distribution does not
make a dierence in the parameter estimates. In conclusion, the results of these sensitivity
analyses regarding the proposal distributions rearm the comment of Richardson and Green
(1997) that it is rarely worth ne tuning the proposal distribution in Metropolis-Hastings
methods.
We also studied the sensitivity of the results to the chosen prior distributions. First, we
compare the results obtained by using the Beta(3,2) and Beta(1,1) distributions as priors
for all 's. Note that the Beta(1,1) is just the U(0;1) distribution and we used it as priors
for the 's in all of our earlier simulations. Also, recall that the Beta(3,2) is the distri-
bution from which the  values (probability that a family is of linked type) were actually
generated in all simulations. Both distributions gave comparable results, indicating that the
simulated data are informative enough to overwhelm the eect of prior distributions. We
15also examined the sensitivity of the prior for d. Although we use a non-informative prior by
setting d<1 = 1=22, another possible non-informative prior is to let d<1 = (length of the
chromosome)/(total genome length excluding sex chromosomes). For chromosome 21, this
is approximately 0.017. Apart from these two non-informative priors, we also considered an
informative prior of d<1 = 0:1 (relevant for applications in which some a priori knowledge
is available). The results from the three priors in terms of BF were the same, due to the
fact that BF is independent of d<1 (Richardson and Green 1997), rearming its value as
a model selection tool.
4 EFFECT OF DISEASE MODEL
MISSPECIFICATION
In real applications of any parametric approach in linkage analysis (as in our real data anal-
yses to be described in the next section), since the true disease model is unknown, usually
an approximate model is used. So a natural question is what is the eect of model misspec-
ication. We investigated this issue for the proposed Bayesian approach by analyzing the
simulated data of GAW13, consisting of 100 replicates that have been simulated to mimic
the real data from the Framingham Heart Study (Almasy et al. 2003). The model used for
simulation is extremely complex with about 50 trait genes that interact via complicated rela-
tionships to produce various traits. We considered the simulated trait \high blood pressure
(HBP)". In the simulating model, HBP is aected by several genes over several chromosomes.
We particularly focused on chromosome 21 as it has three genes, b37, s12, and s10, located
at (sex-averaged distance) 25.31, 25.64, and 49.77 cM, respectively, that directly aect blood
pressure. The phenotypic data for each person were taken over a range of time. So to label
whether a person is aected by HBP, we combined the longitudinal data on blood pressure
and another closely related variable, hypertensive treatment using the criterion of Biswas et
al. (2003). The marker data are as described in the section Simulation Results. Note that
b37 and s12 lie between markers 3 and 4 while s10 lies between markers 5 and 6.
We analyzed each of the 100 replicates using the following two models, where D is the
16disease allele. Model I is the intermediate model used in the simulation study; it is the kind
of incomplete penetrance model that one might use as an approximation to the true but
unknown complex model. Model II has P(D) = 0.3, P(A jDD) = 0.8, P(A jDd) = 0.4,
and P(A jdd) = 0. It corresponds to the average of the disease gene s10's simulating models
for the systolic and diastolic blood pressures. Figure 2 shows a scatter plot of pairs of d BF
values (one from each of the two models) in the log scale, and a side-by-side plot of the 95%
CSs and associated ^ m values from the the two models. The results are similar under the two
models. Out of the 100 replicates, there is evidence for linkage in 81 of the replicates under
model I and in 82 under model II. There are three replicates for which model I gives signals
but model II does not, and vice versa is true in four other replicates. A closer look at the
top plot reveals that the log(d BF) values for model II tend to be slightly larger than their
counterparts for model I, reected in having more points cluttered below the diagonal line.
Also, there is a little less variability associated with model II as represented by the shorter
CSs compared to model I. Since model II species zero phenocopy rate and is closer to the
true models of s10, it seems that it performs slightly better in terms of showing stronger
linkage signals and yielding ^ m values and CSs closer to the true location of s10. However,
more CSs under model I capture the other two disease genes than those under model II.
This observation is worth further discussion. In the majority of the replicates, the values of
^ m lie between markers 5 (at 40.07 cM) and 6 (at 59.53 cM), i.e., the gene s10 is detected.
However, the actual values of ^ m in many of the replicates are o from the true location of
s10; rather, they are pulled towards the center of the chromosome. This seems to be the
eect of the other two genes, which are detected in a few of the replicates, especially under
model I. These observations are, in fact, consistent with the simulating model in which the
eects of b37 and s12 are much lower (low penetrances) on blood pressure than s10. The fact
that model II is closer to the true model for gene s10 makes it less likely to be able to detect
the other two genes. Finally, returning back to our primary question, we note that results
from both models are very similar, leading us to conclude that this approach is reasonably
robust to model misspecication.
175 APPLICATIONS TO TWO DATASETS
5.1 Lung Cancer
The GELCC dataset consists of 52 extended pedigrees. Bailey-Wilson et al. (2004) analyzed
these data using an autosomal dominant model with a disease allele frequency of 0.01, and
penetrances of 10% and 1% for disease allele carriers and non-carriers, respectively. Using
the full dataset, they found a maximum HLOD score of 2.79 on chromosome 6, which is a
bit short of the traditional cuto of 3 to conclude linkage.
We considered the same 52-pedigree dataset and applied the Bayesian approach to the
chromosome 6 data. There are 18 markers on chromosome 6 with an average heterozygosity
of 0.72 and an average inter-marker distance of 10.47 cM. The LOD scores are obtained from
SIMWALK2 (Sobel and Lange 1996) using the same disease model as that used by Bailey-
Wilson et al. (2004). We used the same non-informative priors for d and 's as used in
the simulation study. This yielded d BF = 31.94, exceeding the threshold of 25 for declaring
linkage by a substantial margin. The point estimate, ^ m, and the 95% CS for the location
of the disease gene are 157.56 cM (near marker D62436), and (146, 169) cM, respectively.
The CS covers three markers, namely, C6S1848, D6S2436, and D6S1035, and overlaps a
genomic region on the q arm of chromosome 6 that exhibits allelic loss in non-small-cell lung
carcinoma (Bailey-Wilson et al. 2004). As to be elaborated in the Discussion section, the
apparent failure of the admixture approach was due to the variable rates of heterogeneity in
the dataset, which reduces its power to detect linkage. In contrast, by accounting for this
variability across dierent families, the Bayesian approach is able to extract the information
contained in the dataset to detect the linkage signal.
5.2 Asthma
Of the three asthma samples, two are from the Collaborative Study on the Genetics of
Asthma (CSGA), namely Caucasians (S1) and African Americans (S2), and the third is
a German sample (S3). S1, S2, and S3 consist of 112, 113, and 97 families, respectively.
Eerdewegh et al. (2001) computed several heterogeneity statistics using these datasets.
18HLOD did not give any linkage signal. HLOD-C (Vieland et al. 2001), an extension of
HLOD, wherein each of the three samples are assigned a separate  parameter, showed some
signal on chromosome 6. However, it is not clear whether this can be considered as a sig-
nicant evidence since HLOD-C involves more parameters than HLOD, and hence needs a
higher cuto than HLOD (see Biswas (2003) for details). A major reason for diminished
linkage signal is that the sample S2 has virtually no linked families, which washes out mod-
erate signals contained in S1 and S3 (Eerdewegh et al. 2001; Wang et al. 2001; Biswas and
Lin 2004).
Based on the above ndings, we decided to analyze chromosome 6 data using the disease
model used in Eerdewegh et al. (2001): dominant model with a disease allele frequency
of 10.56%. The two CSGA samples and the German sample consist of 21 and 19 markers
on chromosome 6, respectively, with only a few markers in common. The markers in these
two types of samples have almost the same average heterozygosities, 0.77 and 0.79, and are
separated by 9.7 cM on the average. The LOD scores were calculated using GENEHUNTER
(Kruglyak et al. 1996). The prior distributions for the  parameters in the S1, S2, and
S3 samples were set to be Beta(1,1), Beta(1,8), and Beta(1,1), respectively. These priors
incorporates our a priori information (knowledge provided by the data collectors and through
their and others' prior analyses) that S2 consists of mostly unlinked families. The disease
gene location parameter, d, was assigned the same non-informative prior as in the simulation
study. We obtained d BF = 102.5. Less informative priors for the 's of the S2 families were
also entertained, including Beta(1,5), Beta(2,10), and Beta(1,4); all yielded strong evidence
for linkage, with an estimated BF of at least 31.5. The estimated gene location and 95%
CS are rather invariant to the priors used, and they are around 46 cM and (38, 52) cM,
respectively. This CS contains the estimates reported by Eerdewegh et al. (2001) and Wang
et al. (2001) as well as the point and interval estimates in Biswas and Lin (2004), suggesting
that we may have narrowed down the disease gene to a correct interval.
196 DISCUSSION
The problem of heterogeneity in human genetics is very complicated but important for
mapping genes responsible for complex traits. We address this problem through a Bayesian
approach by taking advantage of the general MCMC methodology and one of its more recent
developments on tackling model selection issues, the reversible jump algorithm. We have
shown that the proposed Bayesian approach can be much more powerful than the currently
used admixture approach with a single  parameter. This holds true also for data generated
under complicated disease models not considered here, such as the GAW14 simulated data,
which are generated under an epistasis model involving four disease genes and two modifying
loci (Biswas, Lin, and Berry 2005). Notably, this power gain does not lead to an increase in
false positive rates. In addition, interval estimates of parameters are readily available with
known properties under the stated assumptions. Today, there is a much greater need for
reliable interval estimates in linkage analysis as the focus in genetic studies has been shifted
from testing whether a chromosome harbors a disease gene to narrowing the gene down to
a small chromosomal region for ne mapping and association studies. We found that this
approach is sensitive neither to proposal parameters involved in the MCMC moves nor to
disease model misspecication.
In regard to the condence interval estimates, we found that the ones obtained from the
ordinary batch means approach are too narrow to capture the true value of d. This may
serve as a cautionary note on relying on batch means' SE to estimate the true SE in other
applications. A potential alternative method might be to use the xed-width approach
(Jones, Haran, Cao, and Neath 2006) which can guard against under estimation of SE,
although it is not clear whether the method can be easily adapted to the setting here. We
found that the Bayesian credible sets provide reasonable interval estimates. With missing
data and coarse marker map, they may be a little wider than what one would like. However,
our simulations under the ne mapping setting show that the CSs given by the Bayesian
approach localizes the disease gene in reasonably narrow intervals. With complete data,
further narrowing of the CSs are observed. Another alternative interval estimate is the
highest posterior density (HPD) set. An HPD set may be narrower than the usual credible
20sets but it may consist of disjoint intervals. For the point estimate of the location of the
disease gene, we have also explored posterior median and mode, besides mean, and we found
the three statistics to give similar results in our simulations.
For the 52-pedigree lung cancer dataset, the ability of the Bayesian method to detect
the linkage signal while the admixture approach failed to do so, rearms our conclusion
of increased power of the Bayesian approach drawn from our extensive simulation study.
Since our simulation results indicate that the increase in power for the Bayesian approach
does not come at the expense of inated false positive rate, we are quite condent that the
identied linkage region harbors a true disease locus. Our conclusion is further strengthened
by a subset analysis performed in Bailey-Wilson et al. (2004). By focusing on a subset of 23
pedigrees that were believed to have minimal heterogeneity, a signicant signal was detected.
Their point estimate is very close to ours and is contained in our 95% CS. Two aspects of our
investigation are noteworthy. First, in addition to the point estimate, the Bayesian approach
also provides an interval estimate for the gene location with known statistical properties, a
feat unmatched by the subset analysis. Second, there are known shortcomings of subset
analysis, the most notable being power loss unless the stratication factor(s) adequately
represents heterogeneity (Leal and Ott 2000).
In the GAW12 asthma application, we saw how a priori information can be used to
form informative priors, which in turn can increase the power to identify linkage. In fact,
if we use non-informative U(0,1) priors for all the 0s in the three samples, no linkage
signal is obtained. So we recommend gaining some information about the  parameters and
incorporating it via informative priors. An important dierence between the sample S2 and
the other two samples, S1 and S3, is ethnicity. Such factors, which may discriminate between
various heterogeneity levels, can be used to form groups and then HLOD-C can be applied
to get some ideas about the 's. Another way of grouping is according to distributions of
families as discussed in Lin and Biswas (2004), but this grouping scheme may not be realistic
in most applications other than experimental crosses. Alternatively, one may simply examine
the homogeneity LOD score curves for each family to get a sense of the probabilities that
they are of linked type.
Another level of exibility can be added to the Bayesian approach when covariate infor-
21mation that can help discriminate between families is available. For example, if race (age
of disease onset) is a discriminating factor in determining the linked type of a family, as in
the GAW12 dataset (breast cancer), then hierarchical priors for the 's can be reasonably
introduced. More specically, we can let the  parameters follow dierent distributions with
hyper priors determined by their covariate values.
In this paper, we have presented a Bayesian approach in the context of localizing one
disease gene at a time, i.e., marginal analysis. We note that the reversible jump MCMC
mechanism employed here readily allows for treating the number of disease genes as an un-
known parameter, and simultaneous mapping of the disease genes (joint analysis). This type
of analysis will be especially useful in mapping more than one gene on the same chromo-
some. The basic framework of this general case has been outlined elsewhere (Biswas 2003).
Nonetheless, since marginal analysis is still pre-dominant in real data analysis, and joint
analysis would certainly be more intricate, it is more logical to rst investigate the method
for marginal analysis. In practice, such a single gene analysis may still shed light on the
existence of multiple disease loci. A strong linkage signal coupled with a wide CS and a
disjoint HPD set may be indicative of the presence of more than one gene on the chromo-
some. Such a predicament was observed in our analysis of the GAW13 data, which contain
two distinguishable genes (by linkage analysis) on chromosome 21. For joint analysis, which
is the subject of a future research project, hierarchical modeling as discussed above will be
much more important as the number of  parameters will go up dramatically.
Appendix A
Four move types: L ! L, L ! U, U ! U, and U ! L
In an L ! L move, we update each of the parameters in  using Gibbs sampler by sam-
pling from the conditional distribution of (jj( j);d;x), j = 1;:::;k, where ( j) is the
remaining set of elements of  excluding j. To do this, we note that
(jj( j);d;x) / j(j)

j
Lj(djxj)
Lj(1jxj)
+ (1   j)

; 0  j  1:
22For the special case of uniform priors for all j's, i.e., j(j) = 1; 0  j  1; for all j, we can
nd the normalizing constant for the above distribution and hence we use the simple inverse
cdf method to sample from (jj( j);d;x). This case may arise in many applications where
there is no prior information about the j's and so this is a natural non-informative prior
to use. For the general case of any other prior distribution j(j), (jj( j);d;x) may not
be available in closed form and so inverse cdf method cannot be used. In this case, we use
rejection sampling. A detailed description of both cases can be found in Biswas (2003).
After updating , in an L ! L move, we update d using a Metropolis-Hastings algorithm.
Note that
(dj;x) / d<1d(Id)
k Y
j=1

j
Lj(djxj)
Lj(1jxj)
+ (1   j)

= g(d); d < 1:
Let d(t) be the value of d at iteration t and s be a pre-specied integer. At (t+1)th iteration,
we select Id from the set of integers in the range

maxf1;Id(t)   sg;minfId(t) + s;Ng

, with
equal probability of selecting each integer in this set. So, the chosen d can be d(t) itself or
any of the s neighboring distance values of d(t), unless d(t) is near the beginning or the end
of the chromosome. Let us denote this probability mass function by f(djd(t)). We accept d
as the next value of d, i.e., d(t+1) = d, with probability min
n
1;
g(d)f(d(t)jd)
g(d(t))f(djd(t))
o
. If d is not
accepted, d(t+1) = d(t).
An U ! U move does not involve updating of any parameters, so we simply set d(t+1) =
1.
When an U ! L move is proposed, we need to generate (;d) since the U state has no
parameters. Each j is chosen randomly from a distribution, pj(j), and Id is selected from
the set f1;:::;Ng with respective probabilities fP1;:::;PNg. We accept this move with
probability minf1;A(;d)g, where
A(;d) =
d<1d(Id)
Qk
j=1 j(j)
d=1

Qk
j=1
h
j
Lj(djxj)
Lj(1jxj) + (1   j)
i
1

1   1
(1   2):PId:
Qk
j=1 pj(j)
 j1j:
Note that A(;d) is the product of prior ratio, likelihood ratio, proposal ratio, and Jacobian
of the transformation. If this move is accepted, the generated  and d are taken as (t+1)
and d(t+1), respectively, otherwise the chain stays in the U state, i.e., d(t+1) = 1.
23The move L ! U is opposite of the move U ! L. So, it is accepted with the proba-
bility minf1;A 1((t);d(t))g. If it gets accepted, ((t);d(t)) are discarded and d(t+1) = 1.
Otherwise the chain stays in the L state with ((t+1);d(t+1)) = ((t);d(t)).
We use 1 = 2 = 0.5 and s = 5. In the U ! L move, pj(j) is taken to be U(0;1) for all j,
and Pi, i = 1;:::;N, are calculated using a discretized and truncated normal distribution.
Appendix B
Asymptotic Joint Distribution of Estimators (^ p; ^ m)
Divide the total realizations for d (excluding the burn-in period) into R batches, each of
length L. Let d
(l)
r denote the lth value of the distance in the rth batch, l = 1;2;:::;L; r =
1;2;:::;R. Dene two functions, f(d) = dI(d < 1) and g(d) = I(d < 1). Also, let
yr =
PL
l=1 f(d
(l)
r )=L and pr =
PL
l=1 g(d
(l)
r =L, r = 1;2;:::;R. Then the following results
are apparent by applying a standard Markov chain Central Limit Theorem (Chung 1967).
For large L,
np
L(yr   m);r = 1;2;:::;R
o
and
np
L(pr   p);r = 1;2;:::;R
o
are approx-
imately iid samples from N(0;2
f) and N(0;2
g), respectively, where m = Ef(d) = E(yr)
and p = Eg(d) = E(pr).
Now, consider the estimators ^ p and ^ m. We can rewrite them in terms of the f and g
functions as
^ m =
PR
r=1
PL
l=1 f(d
(l)
r )
PR
r=1
PL
l=1 g(d
(l)
r )
=
PR
r=1 yr=R
PR
r=1 pr=R
=
 y
 p
; for  p 6= 0;
^ p =
1
R
R X
r=1
1
L
L X
l=1
g(d
(l)
r ) =
1
R
R X
r=1
pr =  p:
By invoking the bivariate Central Limit Theorem and the bivariate Delta Method (Lehmann
1999),
p
R(^ p   p);
p
R(^ m   m)

 BV N(0;0;11;22;12); approximately;
24where
11 =
"
@h
@ y
2
V ar(yr) + 2

@h
@ y

@h
@ p

Cov(yr;pr) +

@h
@ p
2
V ar(pr)
#
 p=p; y=m
= V ar(pr);
22 =
"
@k
@ y
2
V ar(yr) + 2

@k
@ y

@k
@ p

Cov(yr;pr) +

@k
@ p
2
V ar(pr)
#
 p=p; y=m
=

m
p
2 
V ar(yr)
m2  
2Cov(yr;pr)
mp
+
V ar(pr)
p2

;
12 =

@h
@ y
@k
@ y
V ar(yr) +

@h
@ y
@k
@ p
+
@h
@ p
@k
@ y

Cov(yr;pr) +
@h
@ p
@k
@ p
V ar(pr)

 p=p; y=m
=
1
p
Cov(yr;pr)  
m
p2 V ar(pr):
Hence, ^ p and ^ m are consistent estimators of p and m, respectively (when both L ! 1
and R ! 1). We note that these results are not the standard ones. Although each batch
consists of a xed number (L) of realizations, the number of realizations in each batch that
correspond to the linked model (d < 1) are random and ^ m is based on the realizations
from the linked model only. Finally, we also note that the simultaneous (1-)% condence
intervals for (m, p) can also be obtained, if so desired.
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28Table 1: Test statistics Zy and Zp for independence of batch means yr's and pr's, respectively.
Hypothesis of independence is rejected at 5% level if jZj > 1:96, where 1.96 is the 2.5%
quantile of the N(0;1) distribution.
da Zy Zp ^ p d BF ^ m SE(^ m)b 95% CI 95% CS
5.00 0.585 1.257 0.946 367.9 6.46 0.091 (6.28,6.64) (-8,23)
13.00 -0.758 -0.788 0.989 1888.1 10.32 0.042 (10.24,10.40) (1, 18)
25.64 -0.316 0.198 0.876 148.4 16.38 0.046 (16.29,16.47) (6,27)
38.00 0.644 1.441 0.589 30.1 39.02 0.077 (38.87,39.17) (12,52)
49.77 -0.886 -1.668 0.724 55.1 44.84 0.055 (44.73,44.95) (33,61)
a: True disease gene location (in cM).
b: Batch means SE based on 30 batches.
29Table 2: Bayesian and admixture approach results at various positions of the disease gene,
d (in cM), and various models. Columns 5-8 are about the estimated disease gene location
under either approach and are computed over samples showing linkage signals.
Model d Method Power a Mean SD Mean 95% CSb % CS containing d
Int 5.00 Bayesian 67.0 5.90 5.49 (-6.78, 20.12) 98.81
Admix. 44.4 4.87 5.28
Int 13.00 Bayesian 72.0 12.30 5.32 (-0.68, 26.06) 98.89
Admix. 50.4 11.68 4.69
Int 25.64 Bayesian 73.6 25.05 5.87 (12.83, 38.74) 97.28
Admix. 46.8 24.28 5.55
Int 38.00 Bayesian 75.8 38.22 5.32 (25.13, 51.51) 100.00
Admix. 54.8 38.06 5.97
Int 49.77 Bayesian 58.4 47.16 8.13 (30.60, 62.87) 93.84
Admix. 36.2 47.97 7.79
Dom 25.64 Bayesian 80.4 24.76 5.27 (14.01, 36.71) 97.26
Admix. 60.2 24.32 5.41
Rec 25.64 Bayesian 41.0 26.43 6.10 (11.80, 42.62) 98.54
Admix. 18.6 25.82 6.18
Hom 25.64 Bayesian 84.6 25.64 4.51 (13.85, 38.94) 99.29
Admix. 71.8 25.43 4.60
Int 25.64 c Bayesian 85.4 25.67 2.99 (18.53, 32.67) 96.25
Admix. 65.2 25.66 4.08
a: percentage of samples showing linkage signals.
b: CS with negative lower limit contains positions beyond the rst marker located at 0 cM.
c: a ner map of markers is used as described in the text.
30Figure 1: Diagnostic plots for a sample generated with the disease gene located at 25.64 cM.
Seven chains are run, each from a dierent starting point. Top plot shows ^ p and bottom plot
shows ^ m.
Figure 2: Analysis of 100 GAW13 simulated replicates using both disease models I and
II. Top: scatter plot of pairs of log(d BF) values for the two models. The dashed lines
represent log(25). The discordant pairs (replicates for which the two models lead to dierent
conclusions) are marked with a \+" symbol. Bottom: plot of 95% CSs (lines) and ^ m values
(circles). The solid lines and circles are for Model I while the dashed lines and open circles
are for Model II. These are plotted for a replicate only if d BF > 25 for both models. The
three horizontal gray lines represent the locations of the three disease genes.
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